Relevant bibliographies by topics / Breast cytology

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Breast cytology'

Author: Grafiati
Published: 11 December 2022
Last updated: 25 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast cytology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast cytology"

1

Wood, M. E., M. Stanley, and G. Leiman. "Ductal lavage (DL) of affected and unaffected breasts in women with newly diagnosed breast cancer: Can this technique be used for risk assessment?" Journal of Clinical Oncology 24, no. 18_suppl (2006): 1024. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.1024.

Full text
Abstract:
1024 Background: Ductal lavage (DL) is designed to obtain cellular material from breast ducts. The use of DL in risk assessment is under investigation. The aim of this study was to evaluate cytologic findings in DL of affected and unaffected breasts in women undergoing definitive surgery for breast cancer. Methods: Women with newly diagnosed breast cancer participated prior to surgery. Women with prior breast cancer or receiving neoadjuvant therapy were excluded. The study was IRB approved; all women gave written informed consent. Women underwent nipple aspiration followed by ductal lavage of fluid-producing ducts for both the affected and unaffected breast in the operating room prior to surgery. Cytology was interpreted as insufficient cells to make a diagnosis (ICMD), benign, mildly or markedly atypical, or malignant. Results: Twenty-three women aged 32–74 years underwent nipple aspiration of both breasts prior to definitive surgery; 1 had bilateral breast cancer. One woman had DCIS, 1 T1a, 3 T1b, 9 T1c, 6 T2, and 4 T3 lesions. Node status was N0 in 13, N1mic in 3, N1 in 5 and N2 in 3 (15 underwent sentinel node evaluation). Five women produced no NAF and therefore did not undergo DL; 18 underwent DL of at least one breast. Cytology samples were available for 30 breasts, 16 affected and 14 unaffected. Two samples contained malignant cells (one from a patient with pre-existing malignant nipple discharge), 3 moderate atypia, all from affected breasts. Benign cytology was found in 20 samples (8 affected breasts) and ICMD was classified in 5 samples (3 affected breasts). Age (</> 50), tumor size, nodal status, or sentinel node procedure were not associated with NAF production, success or cytology of DL. Conclusion: These findings suggest that DL is not effective in identifying known breast cancer. It brings into question its ability to identify women at increased risk. Future research should focus on molecular markers of risk or other means of tissue retrieval. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
2

Anderson, Neil. "Breast cytology." Diagnostic Histopathology 18, no. 9 (2012): 397–99. http://dx.doi.org/10.1016/j.mpdhp.2012.08.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Feichter, George E., Felix Haberthür, Susan Gobat, and Peter Dalquen. "Breast Cytology." Acta Cytologica 41, no. 2 (1997): 327–32. http://dx.doi.org/10.1159/000332520.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Yi Jun. "Gynecomastia With Marked Cellular Atypia Associated With Chemotherapy." Archives of Pathology & Laboratory Medicine 126, no. 5 (2002): 613–14. http://dx.doi.org/10.5858/2002-126-0613-gwmcaa.

Full text
Abstract:
Abstract Gynecomastia is a common benign male breast disease, which may exhibit mild cellular atypia in cytology specimens. However, marked cytologic atypia can be seen in gynecomastia superimposed by chemotherapy. The case described in this report demonstrated severe cytologic atypia of gynecomastia mimicking carcinoma in a patient treated with chemotherapy for acute leukemia. A distinct cytologic feature helpful in avoiding the diagnostic error is described, namely, atypical cells admixed with bland ductal cells and appearing at a different plane. The importance of applying strict diagnostic criteria in breast cytology and clinical correlation is also emphasized.
APA, Harvard, Vancouver, ISO, and other styles
5

Kurian, A. W., V. B. Sharma, E. J. Schwartz, et al. "A phase II breast cancer chemoprevention study of lovastatin in high-risk women: Initial feasibility data." Journal of Clinical Oncology 25, no. 18_suppl (2007): 1502. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1502.

Full text
Abstract:
1502 Background: More than 250,000 U.S. women have high inherited breast cancer risk; many develop hormone-receptor negative (ER/PR-) tumors, for which no chemoprevention exists. Pre-clinical data suggest that hydrophobic HMG-CoA reductase inhibitors (statins) may reduce risk of ER/PR- breast cancers. We report initial feasibility results of a phase II study of lovastatin for breast cancer chemoprevention. Methods: Study Design: Single-arm, non-randomized phase II study. Agent: Lovastatin 80 mg daily for 6 months. Primary Endpoint: Change in proportion of women with atypical cytology on 2-quadrant random periareolar fine needle aspiration (rpFNA) of breast duct cells before and after lovastatin. Secondary Endpoints: Changes in Ki-67, ER/PR, and elevated levels of oxidative DNA damage (ODD) measured by single-cell gel electrophoresis (Comet) assay of breast duct cells; changes in mammographic density; breast cancer incidence. Eligibility: BRCA1/2 mutation carrier, or estimated lifetime risk = 20% due to family history. Statistical Considerations: Planned sample size of 60, yielding 90% power to detect 50% change in proportion with atypia. Results: Twenty participants enrolled in Year 1; 15 have pre-study rpFNA and 5 have post-study rpFNA results to date. Pre-Study Cytology: N=15: 1 (7%, 95% confidence interval 0–32%) had insufficient, 11 (73%, 48–90%) had normal, and 3 (20%, 6–46%) had atypical cytology. Pre-Study Comet Assay: N=4 to date, 2 with atypical and 2 with normal pre-study cytology: 2 with atypical cytology (100%, 29–100%) had a positive Comet assay for elevated ODD, but 0 with normal cytology (0%, 0–71%) had a positive Comet assay. Post-Study Cytology: N=5, 1 with atypical cytology pre-study: 5 (100%, 51–100%) were normal post-study. Post-Study Comet Assay: N=1 to date, with atypical cytology and positive Comet assay pre-study: cytology was normal and Comet assay negative post-study. The study has been well-tolerated, with no drop-out. Conclusions: An early-stage chemoprevention study of lovastatin for 6 months, including 2 rpFNAs, appears feasible in high-risk women. Early results suggest a correlation between cytologic atypia and elevated levels of ODD, and the possibility that lovastatin might reverse these abnormalities. Accrual is ongoing. No significant financial relationships to disclose.
APA, Harvard, Vancouver, ISO, and other styles
6

Creager, Andrew J., Jo Ann Shaw, Peter R. Young, and Kim R. Geisinger. "Intraoperative Evaluation of Lumpectomy Margins by Imprint Cytology With Histologic Correlation." Archives of Pathology & Laboratory Medicine 126, no. 7 (2002): 846–48. http://dx.doi.org/10.5858/2002-126-0846-ieolmb.

Full text
Abstract:
Abstract Background.—Several well-controlled studies have demonstrated significantly increased local recurrence rates in patients with low-stage breast carcinoma treated with breast conservation therapy in whom focally positive margins were not reexcised. Imprint cytology is a rapid technique for evaluating surgical margins intraoperatively, thus allowing reexcisions to be performed during the initial surgery. The large majority of studies on the use of intraoperative imprint cytologic examination of breast conservation therapy margins have been performed at university-based academic centers. Objective.—To evaluate the utility of intraoperative imprint cytologic evaluation of breast conservation therapy margins in a community hospital setting. Methods.—We retrospectively reviewed the intraoperative imprint cytology margins of 141 lumpectomy specimens that had been obtained from 137 patients between May 1997 and May 2001. Results.—We evaluated 758 separate margins. On a patient basis, the sensitivity was 80%, the specificity was 85%, the positive predictive value was 40%, the negative predictive value was 97%, and the overall accuracy was 85%. There were no cytologically unsatisfactory margins. Conclusions.—Imprint cytology is an accurate, simple, rapid, and cost-effective method for determining the margin status of breast conservation therapy specimens intraoperatively in the community hospital setting. This method allows a survey of the entire surface area of the lumpectomy specimen, which is not practical using frozen section evaluation.
APA, Harvard, Vancouver, ISO, and other styles
7

Makhija, Shreya, and S. B Patil. "Cytology of breast-lesions." IP Archives of Cytology and Histopathology Research 5, no. 1 (2020): 81–85. http://dx.doi.org/10.18231/j.achr.2020.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Solla, Julio A., Michael J. Walters, and Daniel Rosenthal. "Breast Cyst Aspiration Cytology." Military Medicine 151, no. 12 (1986): 653–54. http://dx.doi.org/10.1093/milmed/151.12.653.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hajdu, Steven I., and James P. Gastond. "Aspiration Cytology of Breast." Clinics in Laboratory Medicine 11, no. 2 (1991): 357–68. http://dx.doi.org/10.1016/s0272-2712(18)30560-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ciatto, S., M. Rosselli Del Turco, D. Ambrogetti, et al. "Solid nonpalpable breast lesions." Acta Radiologica 38, no. 5 (1997): 815–20. http://dx.doi.org/10.1080/02841859709172416.

Full text
Abstract:
Purpose: To evaluate the contribution of guided fine-needle aspiration cytology in reducing unnecessary biopsies of benign solid nonpalpable breast lesions with low suspicion of malignancy at mammography. Material and Methods: An evaluation was made of a consecutive series of 2444 solid nonpalpable breast lesions detected by mammography and undergoing guided (sonography or stereotaxy) fine-needle aspiration cytology. Surgical biopsy was made in the presence of strong suspicion of malignancy at mammography and/or of abnormal cytology. Results: The sensitivity was 96.7% and the specificity 77.7% (average follow-up 2.77 years). False-negative/inadequate cytology associated with low suspicion of malignancy at mammography resulted in a diagnostic delay in 27 cancer cases (invasive 20, intraductal 7). On the other hand, cytology led to surgical biopsy in 53 cancer cases which might not otherwise have been biopsied because of low radiological suspicion of cancer. Surgical biopsy of all cases, to avoid diagnostic delays, would have increased the benign biopsy rate by a factor of 4.5, with a rise in the benign: malignant biopsy ratio from 0.44:1 to 1.93:1. Conclusion: Stereotaxy- or ultrasound-guided fine-needle aspiration cytology of nonpalpable mammographic abnormalities can achieve a sharp reduction in unnecessary benign biopsies in cases of low suspicion of malignancy at mammography.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Breast cytology"

1

Leung, Nga-shan Phyllis. "Cytological features in equivocal diagnoses (C3/4) of breast fine needle aspiration cytology /." View the Table of Contents & Abstract, 2006. http://sunzi.lib.hku.hk/hkuto/record/B36433883.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Leung, Nga-shan Phyllis, and 梁雅珊. "Cytological features in equivocal diagnoses (C3/4) of breast fine needle aspiration cytology." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B45010791.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kuruppu, Anchala. "The role of HER family signalling in breast cancer." Thesis, University of Nottingham, 2016. http://eprints.nottingham.ac.uk/33685/.

Full text
Abstract:
The HER family of receptors plays a major role in a variety of cancers including breast cancer. Several researchers have shown that HER family overexpression in breast cancer is a significant prognostic factor, especially for survival and relapse. Therefore, many therapeutics are being developed to test the impact of HER family blockade in breast cancer. Although numerous therapies have been developed, many have not been very successful in the clinic. This is often a consequence of cancer cells developing new mechanisms to activate HER family signalling indirectly through cross talk with compensatory pathways. Thus, it is vital to consider the biology of the HER signalling network to a greater extent, which includes RAS/MAPK, PI3K/AKT, mTOR, JAK/STAT, ER and AhR pathways and, also identify breast cancer patient populations that will benefit from specific targeted therapies that target these pathways. In the current study, 6 breast cancer cell lines (MCF7, T47D and ZR-75-1, SKBR3, MDA-MB 468 and MDA-MB 231) representing distinct molecular subtypes of breast cancer have been used to investigate anti-cancer effects of a variety of agents. These agents include clinical as well as currently experimental and entirely novel pharmacological agents alone or in combination. Among the clinical agents studied, it was found that EGF and Gefitinib were significantly potent against the HER2 overexpressing SKBR3 cell line, out of the panel of cell lines studied. EGF and Gefitinib showed a slightly different spectrum of activity from each other against the SKBR3 cell line. However, more research is needed to determine whether EGF could be used as a therapy for HER2 overexpressing breast cancer. Even though Gefitinib is currently used as a treatment in the clinic, the therapeutic window of this agent is drastically narrowed by its poor bioavailability, acquired resistance and systemic toxicity. Thus, in the current study, encapsulation of Gefitinib within the cavity of human heavy chain (H) apoferritin (AFt), provided a route for sustained release of Gefitinib from the H-AFt cavity, which demonstrated enhanced anti-tumour activity, at a longer duration against the SKBR3 cell line compared to Gefitinib alone. Overexpression of HER2 is considered to confer a more aggressive phenotype in breast cancer. Many patients have shown resistance to existing clinical agents such as Trastuzumab, demonstrating the need for novel therapies. Hence, 2 novel HER2 targeting human H and light chain (L)-AFt-fusion proteins were tested, and it was found that the nanoagent - H-AFt-fusion protein was very potent against the SKBR3 cell line compared to the L-AFt-fusion protein. This novel H-AFt-fusion protein abolished SKBR3 colony formation completely, caused a G1 arrest and a reduction in the orchestration of S and G2/M cell cycle events and also induced a large SKBR3 apoptotic population demonstrating its potent cytotoxic effects. Furthermore, this agent down-regulated the HER2 protein remarkably which resulted in significant down-regulation of the RAS/MAPK, PI3K/AKT and JAK/STAT signal transduction pathways in SKBR3 cells. Previous research has shown that a combination of pharmacological agents are more effective against cancer than individual agents due to up-regulation of compensatory signalling pathways which cancer cells use to thrive and acquire resistance to agents. Thus, several agents were tested in combination. Out of the agents tested it was found that 3 dual PI3K/mTOR inhibitors were potent against the triple negative breast cancer cell line - MDA-MB 468 and the HER2 overexpressing SKBR3 cell line. Further, Gefitinib in combination with an experimental AhR ligand - 5F 203, showed synergistic growth inhibition against the SKBR3 cell line by inducing CYP1A1, thereby resulting in a large apoptotic population. It was observed that the effect of Gefitinib was mainly potentiated by the effect of 5F 203 within the agent combination. There is a momentous unmet medical need for the development of effective therapies that can stabilise or slow the progression of breast cancer, therefore, these results may contribute to existing knowledge or enhance further understanding of the HER signalling network and therapies targeting this network. It may also guide potential treatment options which might lead to significant improvements in breast cancer therapy in the clinic thereby personalising therapy for patients with breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Leong, Yeh Chwan. "Reprogramming to cancer induced pluripotent stem cells elucidates the contribution of genetic and epigenetic alterations to breast carcinogenesis." Thesis, University of Nottingham, 2018. http://eprints.nottingham.ac.uk/53330/.

Full text
Abstract:
The induced pluripotent stem cells (iPSCs) technology has revolutionized disease modelling by enabling the generation of patient-specific pluripotent stem cells for the study of complex disorders such as cancer. Somatic cell reprogramming through iPSCs induces global epigenetic reconfiguration of the chromatin which converts cancer cells to an embryonic stem cell-like state with potential reversion of tumorigenicity. Therefore, reprogramming can be used to answer the question as to whether epigenetic alterations alone can be sufficient to induce carcinogenesis, independent of genetic defects. In addition, it can used to dissect the relative contribution of genetics and epigenetics and epigenetics to tumorigenicity. In this study, the triple negative breast cancer (TNBC) cell line BT-549 and oestrogen receptor positive (ER+) cell line MCF7 were successfully reprogrammed by using the non-integrative episomal vectors expressing OCT4, SOX2, L-MYC, KLF4, LIN28, EBNA1, shRNA against TP53, and microRNA-302/367 cluster together with treatment of sodium butyrate. Pluripotency of cancer-derived iPSCs was confirmed by RT-PCR, RT-qPCR and immunofluorescence staining for expression of pluripotency markers. Differentiation potential of iPSCs was also assessed by using in vitro differentiation either spontaneous or directed to the mammary lineage. Functional assays indicated potential loss of tumorigenicity in re-differentiated cells derived from cancer iPSCs. The same approach was applied to study an immortalised, non-malignant mammary epithelial cell line MCF10A and two of its derived isogenic lines harbouring the two most frequent mutations in breast cancer, PIK3CAH1047R (+/-) and TP53(-/-), created by using CRISPR-Cas9 gene editing. Reprogramming induced a tumorigenic phenotype in iPSCs (PIK3CAH1047R (+/-) isogenic line only) and re-differentiated progenies (in both wild type MCF10A and PIK3CAH1047R (+/-) cell lines), suggesting the contribution of PIK3CA mutation in enhancing malignant transformation. Results in this study suggested that epigenetics alone and/or its interaction with genetic defects (e.g. PIK3CA mutation) has significant impact on breast cancer carcinogenesis. The dissection of the molecular mechanisms underlying the loss and gain of tumorigenicity using the iPSC models generated in this study could provide general understandings on breast carcinogenesis, which in turn could have important clinical implications.
APA, Harvard, Vancouver, ISO, and other styles
5

Guler, Elif. "Investigaton Of Chemopreventive Properties Ofurtica Dioica L., In Mcf-7 And Mda231 Breast Cancer Celllines." Phd thesis, METU, 2011. http://etd.lib.metu.edu.tr/upload/12613843/index.pdf.

Full text
Abstract:
ABSTRACT INVESTIGATON OF CHEMOPREVENTIVE PROPERTIES OF URTICA DIOICA L., IN MCF-7 AND MDA231 BREAST CANCER CELL LINES. G&uuml<br>ler, Elif Ph.D., Biological Sciences Department Supervisor : Prof. Dr. Mesude
APA, Harvard, Vancouver, ISO, and other styles
6

Erte, Idil. "Bivariate Random Effects And Hierarchical Meta-analysis Of Summary Receiver Operating Characteristic Curve On Fine Needle Aspiration Cytology." Master's thesis, METU, 2011. http://etd.lib.metu.edu.tr/upload/12613619/index.pdf.

Full text
Abstract:
In this study, meta-analysis of diagnostic tests, Summary Receiver Operating Characteristic (SROC) curve, bivariate random effects and Hierarchical Summary Receiver Operating Characteristic (HSROC) curve theories have been discussed and accuracy in literature of Fine Needle Aspiration (FNA) biopsy that is used in the diagnosis of masses in breast cancer (malignant or benign) has been analyzed. FNA Cytological (FNAC) examination in breast tumor is, easy, effective, effortless, and does not require special training for clinicians. Because of the uncertainty related to FNAC&lsquo<br>s accurate usage in publications, 25 FNAC studies have been gathered in the meta-analysis. In the plotting of the summary ROC curve, the logit difference and sums of the true positive rates and the false positive rates included in the meta-analysis&lsquo<br>s codes have been generated by SAS. The formula of the bivariate random effects model and hierarchical summary ROC curve is presented in context with the literature. Then bivariate random effects implementation with the new SAS PROC GLIMMIX is generated. Moreover, HSROC implementation is generated by SAS PROC HSROC NLMIXED. Curves are plotted with RevMan Version 5 (2008). It has been stated that the meta-analytic results of bivariate random effects are nearly identical to the results from the HSROC approach. The results achieved through both random effects meta-analytic methods prove that FNA Cytology is a diagnostic test with a high level of distinguish over breast tumor.
APA, Harvard, Vancouver, ISO, and other styles
7

Favara, David M. "The biology of ELTD1/ADGRL4 : a novel regulator of tumour angiogenesis." Thesis, University of Oxford, 2017. http://ora.ox.ac.uk/objects/uuid:0d00af0a-bb43-44bc-ba0b-1f8acbe34bc5.

Full text
Abstract:
<strong>Background:</strong> Our laboratory identified ELTD1, an orphan GPCR belonging to the adhesion GPCR family (aGPCR), as a novel regulator of angiogenesis and a potential anti-cancer therapeutic target. ELTD1 is normally expressed in both endothelial cells and vascular smooth muscle cells and expression is significantly increased in the tumour vasculature. The aim of this project was to analyse ELTD1's function in endothelial cells and its role in breast cancer. <strong>Method:</strong> 62 sequenced vertebrate genomes were interrogated for ELTD1 conservation and domain alterations. A phylogenetic timetree was assembled to establish time estimates for ELTD1's evolution. After ELTD1 silencing, mRNA array profiling was performed on primary human umbilical vein endothelial cells (HUVECs) and validated with qPCR and confocal microscopy. ELTD1's signalling was investigated by applying the aGPCR ‘Stinger/tethered-agonist Hypothesis'. For this, truncated forms of ELTD1 and peptides analogous to the proposed tethered agonist region were designed. FRET-based 2<sup>nd</sup> messenger (Cisbio IP-1;cAMP) and luciferase-reporter assays (NFAT; NFÎoB; SRE; SRF-RE; CREB) were performed to establish canonical GPCR activation. To further investigate ELTD1's role in endothelial cells, ELTD1 was stably overexpressed in HUVECS. Functional angiogenesis assays and mRNA array profiling were then performed. To investigate ELTD1 in breast cancer, a panel of cell lines representative of all molecular subtypes were screened using qPCR. Furthermore, an exploratory pilot study was performed on matched primary and regional nodal secondary breast cancers (n=43) which were stained for ELTD1 expression. Staining intensity was then scored and compared with relapse free survival and overall survival. <strong>Results:</strong> ELTD1 arose 435 million years ago (mya) in bony fish and is present in all subsequent vertebrates. ELTD1 has 3 evolutionary variants of which 2 are most common: one variant with 3 EGFs and a variant with 2 EGFs. Additionally, ELTD1 may be ancestral to members of aGPCR family 2. HUVEC mRNA expression profiling after ELTD1 silencing showed upregulation of the mitochondrial citrate transporter SLC25A1, and ACLY which converts cytoplasmic citrate to Acetyl CoA, feeding fatty acid and cholesterol synthesis, and acetylation. A review of lipid droplet (fatty acid and cholesterol) accumulation by confocal microscopy and flow cytometry (FACS) revealed no changes with ELTD1 silencing. Silencing was also shown to affect the Notch pathway (downregulating the Notch ligand JAG1 and target gene HES2; upregulating the Notch ligand DLL4) and inducing KIT, a mediator of haematopoietic (HSC) and endothelial stem cell (ESC) maintenance. Signalling experiments revealed that unlike other aGPCRs, ELTD1 does not couple to any canonical GPCR pathways (Gαi, Gαs, Gαq, Gα12/13). ELTD1 overexpression in HUVECS revealed that ELTD1 induces an endothelial tip cell phenotype by promoting sprouting and capillary formation, inhibiting lumen anastomoses in mature vessels and lowering proliferation rate. There was no effect on wound healing or adhesion to angiogenesis associated matrix components. Gene expression changes following ELTD1 overexpression included upregulation of angiogenesis associated ANTRX1 as well as JAG1 and downregulation of migration associated CCL15 as well as KIT and DLL4. In breast cancer, none of the representative breast cancer cell lines screened expressed ELTD1. ELTD1 breast cancer immunohistochemistry revealed higher levels of vascular ELTD1 staining intensity within the tumour stroma contrasted to normal stroma and expression within tumour epithelial cells. Additionally, ELTD1 expression in tumour vessels was differentially expressed between the primary breast cancer microenvironment and that of the matched regional node. Due to the small size of the pilot study population, survival comparisons between the various subgroups did not yield significant results. <strong>Conclusion:</strong> ELTD1 is a novel regulator of endothelial metabolism through its suppression of ACLY and the related citrate transporter SLC25A1. ELTD1 also represses KIT, which is known to mediate haematopoietic and endothelial progenitors stem cell maintenance, a possible mechanism through which endothelial cells maintain terminal endothelial differentiation. ELTD1 does not signal like other adhesion GPCRS with CTF and FL forms of ELTD1 not signalling canonically. Additionally, ELTD1 regulates various functions of endothelial cell behaviour and function, inducing an endothelial tip cell phenotype and is highly evolutionarily conserved. Lastly, ELTD1 is differentially expressed in tumour vessels between primary breast cancer and regional nodal metastases and is also expressed in a small subset of breast cancer cells in vivo despite no cancer cell lines expressing ELTD1. The pilot study investigating ELTD1 in the primary breast cancer and regional involved nodes will be followed up with a larger study including the investigation of ELTD1 in distant metastases.
APA, Harvard, Vancouver, ISO, and other styles
8

Yeo, Chwee Hong Anna. "Anatomical correlation of tear instability in Chinese eyes." Thesis, Queensland University of Technology, 2000. https://eprints.qut.edu.au/36753/1/36753_Yeo_2000.pdf.

Full text
Abstract:
Mucin deficiency is a possible cause of tear film instability. The important sources of mucin are the conjunctival goblet cells and the non-goblet conjunctiva! epithelial cells where the mucin-like glycoproteins are stored in the mucous secretory vesicles. This thesis addresses the relationship between the quantity of the mucin sources and tear film physiology in a group of normal to marginal dry eye Chinese subjects. Chinese subjects were used in this study because they were found to have a lower tear break-up time than Caucasians (Cho and Brown, 1993). Impression cytology techniques were used to obtain conjunctiva! cells and goblet cells from the bulbar conjunctiva! of 61 subjects in order to study the relationship of the goblet cell density and tear film stability. The tear function tests included subjective dry eye symptoms, non-invasive tear break-up time, phenol red thread test and tear break-up time. A second source of mucin supply and tear film stability was also studied. This mucin supply comes from the mucous secretory vesicles of the conjunctival epithelial cells. To study the anatomical structure, the ultrastructure of the conjunctiva! epithelial cells was investigated under the transmission electron microscope. The findings revealed that goblet cell density did not show any correlation with severity of dry eye symptoms, non-invasive tear break-up time, phenol red thread test or tear break-up time test. There are three possibilities for this finding: Deficiency in goblet cell density is not associated with mucin deficiency but mucin de2. Mucin deficiency is not associated with low tear stability but deficiency in goblet cell density remains associated with mucin deficiency. 3. Deficiency in goblet cell density is not associated with mucin deficiency and mucin deficiency is not associated with low tear stability.ficiency remains associated with low tear stability. The negative finding could also be due to the relatively normal and healthy subjects used in the present study. They did not show a great reduction in goblet cell density that could cause an impact on the result. In the counting of goblet cell density using the impression cytology technique, the imprints of the goblet cells might be obtained instead of the whole goblet cells. There was also no significant correlation between dry eye symptoms and tear function tests such as the non-invasive tear break-up time, phenol red thread test and tear break-up time test. This study also found that the gender of the age group between 18 to 28, and contact lens wear of up to three years, would not affect goblet cell density, dry eye symptoms, non-invasive tear break-up time, phenol red thread test and tear break-up time. There was no significant difference in the number of mucous secretory vesicles, microvilli and cell invaginations in the conjunctiva} epithelial cells of subjects with high and low tear stabilities. Therefore, the tear film function may not be associated with the presence of the number of mucous vesicles, microvilli and cells invaginations. On the other hand, the finding could also be due to a small subject sample and the inter-group difference in tear stability might be too small to reflect a difference in the assessment of the ultrastructures. However, a new technique of cell processing for transmission electron microscopy work was also developed for specimens obtained using the impression cytology technique.
APA, Harvard, Vancouver, ISO, and other styles
9

Weigner, Julie. "The true nature of atypical breast cytology." Thesis, 2018. http://hdl.handle.net/1959.13/1383737.

Full text
Abstract:
Research Doctorate - Doctor of Philosophy (PhD)<br>Breast cancer is the most prevalent cancer in women in the western world including Australia. Early detection and accurate diagnosis of new breast lesions is essential for appropriate medical management. Fine needle aspiration (FNA) is a cytological investigative tool commonly used to provide the initial pathological diagnosis of breast lesions. An atypical cytology report (C3) is an ambiguous or equivocal result. This uncertainty creates a dilemma and a more invasive investigative procedure such as core biopsy or incisional biopsy may be required, which comes at greater cost and anxiety to the patient. The aims of this project were to understand the true nature of C3, to determine the underlying causes of C3 and to devise a strategic approach to minimise its use without compromising the other cytological categories. The practical aims were to create a greater understanding of the issue and to produce a collective uniform approach to reporting atypical breast cytology cases thereby refining its use. The results of a blind rescreen of 256 consecutive C3 cases were statistically analysed. From these results, a cytomorphological approach to assess the risk of malignancy was developed and tested against a validation set of 230 subsequent C3 cases. Various strategies have been developed to reduce the incidence of the C3 category. Extrinsic factors can be easily reduced by greater involvement by cytology staff in the FNA procedure. Intrinsic factors can be understood and considered when allocating cases into C3. Specific diagnoses, such as papillary neoplasm can direct more appropriate definitive management. The cytologists in our institution have gained greater awareness of the atypical category by actively participating in the project and by having access to teaching resources and examples. The benefits manifest as financial, medical and social enhancements. It is hoped that some of these approaches will be taken up by other institutions in Australia and internationally.
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Pi-Fang, and 陳碧芳. "Effect of aspiration cytology in the diagnosis of breast cancer." Thesis, 2008. http://ndltd.ncl.edu.tw/handle/trzr48.

Full text
Abstract:
碩士<br>國立中山大學<br>醫務管理研究所<br>96<br>Objective: The incidence rate and mortality of breast cancer are increasing in Taiwan during recent years. The incidence rate of breast cancer is ranked number one among top ten female cancers, and the mortality of breast cancer is ranked fourth among cause of death for female cancer sufferers. The most common age group for breast cancer is between 40 and 50 years old. Breast cancer causes huge disease burdens for individual, family and society. The breast sonography and fine needle aspiration cytology (FNAC) are common screening methods for breast cancer diagnosis. Nevertheless, little study has focused on the benefits of combing these two methods in clinical application. This study aims to fill such research gap. Method: This study conducted medical chart reviews and collected 2,776 observations that were under breast sonography and FNAC examination from a regional hospital locates in southern Taiwan. The diagnosis categories for sonography include: malignant, benign, and probably benign tumor. The diagnosis categories for FNAC include: malignant, benign, and suspicious for malignant. Results: Among 2,776 observations, there were 555 observations (20%) had operation in the studied hospital. The operation results indicated that 205 (36.9%) observations were with malignant status, and 350 (63.1%) observations were with benign status. The diagnosis categories of both sonography and FNAC were significantly associated with the operation results (p<0.001). The FNAC had specificity in 100%, false positive ratio in zero, and positive predictive value in 100%. The Odds ratios for sonography diagnosis categories, age groups, and tumor sizes were OR=4.132 (95%CI: 1.5–11.6), OR=31.957 (95% CI: 3.7–272.4), OR=0.457 (95% CI: 0.1–1.5), respectively. When combining sonography and FNAC in parallel tests, the diagnosis accuracy was 89.2%, sensitivity was 90.2%, specificity was 88.6%, positive predictive value was 82.2%, and negative predictive value was 93.9%. When combining sonography and FNAC in serial testing, the diagnosis accuracy was 88.1%, sensitivity was 67.8%, specificity was 100%, positive predictive value was 100%, and negative predictive value was 84.1%. Conclusion: Combining sonography and FNAC in breast cancer diagnosis can increase the accuracy, decrease false positive ratio and false negative ratio. These two methods can be conducted during outpatient visit and are fast, accurate and cost-effective tools for breast cancer diagnosis. These two methods particularly appropriate for younger female patients for early screening, early intervention, and may increase the survival rates.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Breast cytology"

1

Tse, Gary, Puay Hoon Tan, and Fernando Schmitt. Fine Needle Aspiration Cytology of the Breast. Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-35000-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

K, Kline Irwin, and Howell Lydia Pleotis, eds. Breast. 2nd ed. Lippincott Williams & Wilkins, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

K, Kline Irwin, ed. Breast. Igaku-Shoin, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1946-, Covell Jamie L., ed. Fine needle aspiration cytology and its clinical applications: Breast & lung. American Society of Clinical Pathologists Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Field, Andrew S., Wendy A. Raymond, and Fernando Schmitt, eds. The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-26883-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jan, Drucker, ed. Virus biogenesis, virus receptor interaction, and viruses as tools--milk and mammary gland: Verhandlungen der Gesellschaft für Histochemie auf dem XXXI. Symposion in Gargellen, Montafon (Österreich) vom 20. bis 23. September 1989. G. Fischer, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mouriquand, Jacqueline. Diagnosis of non-palpable breast lesions: Ultrasonographically controlled fine-needle aspiration : diagnostic and prognostic implications of cytologic grading, morphometry, DNA cytometry, immunocytochemistry, and color doppler. Karger, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mouriquand, Jacqueline. Diagnosis of non-palpable breast lesions: Ultrasonographically controlled fine-needle aspirations : diagnostic and prognostic implications of cytologic grading, morphometry, DNA cytometry, immunocytochemistry, and color doppler. Karger, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1952-, Dickson Robert B., and Lippman Marc E. 1945-, eds. Mammary tumorigenesis and malignant progression: Advances in cellular and molecular biology of breast cancer. Kluwer Academic Publishers, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Catania, Salvatore. Breast Cytology in Clinical Practice. Not Avail, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Breast cytology"

1

Oprea-Ilies, Gabriela, and Momin T. Siddiqui. "Breast Cytology." In Atlas of Non-Gynecologic Cytology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-89674-8_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Samedi, Von G., and Thèrése Bocklage. "Breast Cytology." In Pitfalls in Diagnostic Cytopathology With Key Differentiating Cytologic Features. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-39809-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jensen, Kristin C., and Christina S. Kong. "Breast Cytology." In Breast Surgical Techniques and Interdisciplinary Management. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6076-4_49.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pang, Judy. "Breast." In Normal Cytology. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-20336-7_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dey, Pranab. "Breast Swelling." In Fine Needle Aspiration Cytology. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-9772-1_86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schmitt, Fernando, Rene Gerhard, Donald E. Stanley, and Henryk A. Domanski. "Breast." In Atlas of Fine Needle Aspiration Cytology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-76980-6_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Schmitt, Fernando, Rene Gerhard, Donald E. Stanley, and Henryk A. Domanski. "Breast." In Atlas of Fine Needle Aspiration Cytology. Springer London, 2013. http://dx.doi.org/10.1007/978-1-4471-2446-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Florentine, Barbara, and Juan C. Felix. "Fine-Needle Aspiration Cytology of the Breast." In Breast Care. Springer New York, 1999. http://dx.doi.org/10.1007/978-1-4612-2144-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Quintana, Liza M. "Molecular Diagnostics in Breast Cytology." In Molecular Diagnostics in Cytopathology. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-97397-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Moss, S. M. "Screening for Breast Cancer." In New Frontiers in Cytology. Springer Berlin Heidelberg, 1988. http://dx.doi.org/10.1007/978-3-642-73596-7_68.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast cytology"

1

Sumiyoshi, K., T. Nohara, M. Iwamoto, et al. "Usefulness of intraoperative touch smear cytology in breast-conserving surgery." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Niwas, S. Issac, P. Palanisamy, and K. Sujathan. "Wavelet based feature extraction method for breast cancer cytology images." In 2010 IEEE Symposium on Industrial Electronics and Applications (ISIEA 2010). IEEE, 2010. http://dx.doi.org/10.1109/isiea.2010.5679377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Absar, MS, N. Barr, M. Wilson, et al. "Value of axillary ultrasound and cytology in assessing nodal status preoperatively." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Khan, Sana Ullah, Naveed Islam, Zahoor Jan, Hameed Ullah Shah, and Aziz ud Din. "Automated Counting of Cells in Breast Cytology Images Using Level Set Method." In 2018 IEEE 20th International Conference on High Performance Computing and Communications; IEEE 16th International Conference on Smart City; IEEE 4th International Conference on Data Science and Systems (HPCC/SmartCity/DSS). IEEE, 2018. http://dx.doi.org/10.1109/hpcc/smartcity/dss.2018.00258.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

O'Dwyer, Kevin, Katarina Domijan, Adam Dignam, Zhengyuan Tang, Marion Butler, and Bryan M. Hennelly. "Automated raman cytology for the classification of triple negative breast cancer cell lines." In Optics in Health Care and Biomedical Optics XI, edited by Qingming Luo, Xingde Li, Ying Gu, and Dan Zhu. SPIE, 2021. http://dx.doi.org/10.1117/12.2601241.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fazel, MZ, P. Gogalniceanu, A. Patel, et al. "Intra-operative touch imprint cytology for assessing sentinel lymph nodes in patients with lobular breast cancer." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-1008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Liu, Shuo, Jinshu Zeng, Yuhua Wang, et al. "Bayesian network modelling on data from fine needle aspiration cytology examination for breast cancer diagnosis." In 2017 5th International Conference on Frontiers of Manufacturing Science and Measuring Technology (FMSMT 2017). Atlantis Press, 2017. http://dx.doi.org/10.2991/fmsmt-17.2017.86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Filipczuk, Pawel, Marek Kowal, and Andrzej Obuchowicz. "Multi-label fast marching and seeded watershed segmentation methods for diagnosis of breast cancer cytology." In 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2013. http://dx.doi.org/10.1109/embc.2013.6611260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fiori, Mariana, Carlos Marino Cabral Calvano Filho, Pollyanna Dornelas Pereira, Marco Vinícius Fernandes, and Daniela Omar de Souza. "BREAST CRYPTOCOCCOSIS IN IMMUNOCOMPETENT PATIENTS." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1022.

Full text
Abstract:
Introduction: Cryptococcosis is prevalent in immunocompromised individuals. Immunocompetent patients can develop latent infections, the breast being a rare focus of primary disease, with few reports in the literature. Case report: GHMC, female, 27 years old, married, ticketing operator, resident in Valparaíso / GO, Brazil. She denied comorbidities, use of medication, smoking or drinking, as well as contact with caves, farms, farms, wild animals and ingestion of game meat. She reported fever (38°C), left mastalgia associated with hardened erythema with subsequent fistulization and removal of purulent secretion. Upon examination, she was in good general condition, with a palpable nodule of about 6 x 4 cm, in union of the lower quadrants (ULQ) of the left breast (LB), which was regular, soft, felt a little painful on palpation, with increased local temperature and without lymph node enlargement or papillary discharge. The ultrasound of the breasts showed a heterogeneous solid mass, with cystic areas of permeation, in ULQ of LB, of 4.2x2.2 cm, partially defined contours coinciding with a nodular image of 4 cm in the same topography in the mammography. Magnetic resonance imaging showed a nodular, irregular, hypodense image in T1, hyperdense in T2, with parietal enhancement and heterogeneous, progressive internal enhancement, in addition to capturing septa, measuring 6.1x4.0x4.6 cm, suggesting mucinous carcinoma. Core biopsy of the solid part of the lesion and collection of mucinous fluid was performed. Concomitantly, oxacillin was started for seven days. There was no laboratory change during the entire disease period. Fifteen days after the end of the antibiotic use, the lesion became an erythematous lenticular ulcer, with flat edges, of 5.0x4.0 cm, with colloid secretion leaving its bed. Histology showed cryptococcosis, and liquid cytology showed cryptococcus neoformans. During immunosuppression investigation, the patient underwent chest and skull CT scans, serology, tumor markers, ANF (antinuclear factor), rheumatoid factor, C3, C4, lumbar puncture and blood cultures (all excluded any immunosuppressive pathology). The treatment was carried out with Fluconazole 800 mg/day for three months, with a reduction to 300mg/day for another three months. Two months after the start of treatment, the lesion resolved. Cryptococcosis is an invasive mycosis with high morbidity and mortality. It affects immunosuppressed individuals, and is rare in immunocompetent individuals. The main pathogenic species, C. neoformans and C. gatti, are prevalent in tropical and subtropical climates. The main sites affected are the brain and the lungs; other sites are rare. The dosage and duration of breast therapy is unknown, but 2- 3g/day of amphotericin B or 400-800mg/day of fluconazole for 8–12 weeks has achieved therapeutic success in reported cases.
APA, Harvard, Vancouver, ISO, and other styles
10

Sircar, T., G. Thomas, N. Chachlani, et al. "Intra-Operative Assessment of Sentinel Lymph Nodes with Touch Imprint Cytology – Experience on 232 Patients with Breast Cancer." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-1030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Breast cytology' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography